Champions Oncology Announces Geographic Expansion
HACKENSACK, N.J., Dec 13, 2012 (GlobeNewswire via COMTEX) -- Champions
Oncology, Inc. (OTC:CSBR), a company engaged in the development of advanced
technology solutions and services to personalize the development and use of
oncology drugs, announced today the expansion of its personalized oncology
services into the Asian market. The company has been developing the necessary
infrastructure to begin offering its TumorGraft services through a newly
established operation in Singapore. Champions plans to start offering
personalized oncology services by December 31, 2012.
Dr. Ronnie Morris, president of Champions Oncology, commented, "We are very
excited about the opportunity to offer our personalized TumorGraft services to
physicians and cancer patients in South East Asia. The Singapore medical
community has expressed a great deal of interest in offering our services
throughout South East Asia. We believe that this presence will provide a
significant opportunity for growth."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology drugs.
The Company's TumorGraft Technology Platform is a novel approach to
personalizing cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting engraftments, or
Tumorgrafts, in a manner that preserves the biological characteristics of the
original human tumor in order to determine the efficacy of a treatment regimen.
The Company uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology Solutions, in which
results help guide the development of personalized treatment plans, and
Translational Oncology Solutions, in which pharmaceutical and biotechnology
companies seeking personalized approaches to drug development can lower the cost
and increase the speed of developing new drugs. Tumorgrafts are procured through
agreements with a number of institutions in the U.S. and overseas as well as
through its Personalized Oncology Solutions business.
This press release may contain "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Oncology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year
ended April 30, 2012 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions Oncology's future results,
levels of activity, performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking statements
after the date of this press release to conform these statements to actual
results or to changes in Champions Oncology's expectations, except as required
by law.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Champions Oncology
By Staff
CONTACT: CONTACT: Gary Gemignani
Champions Oncology, Inc.
201-808-8408
GGemignani@championsoncology.com
Lauren Kwiecinski
The Trout Group LLC
646-378-2934
lkwiecinski@troutgroup.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: BIOTECHNOLOGY
HEALTH
Company Announcement
